Relapse-free survival (RFS) analysis of the total cohort of patients with breast cancer showed that high EphA2 expression was related to better survival in patients with HER2-negative breast cancers (Fig. 6C) but was not correlated with RFS in patients with HER2-positive breast cancers (Fig. S3B), suggesting that the tumor-suppressive function of EphA2 is dependent on the HER2-negative status in patients with breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.